| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant fragment of human CD79b protein was used as the immunogen for the CD79b antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CD79b Antibody is an antibody targeting CD79b. Host: Mouse. Monoclonal. Clone: CD79b/4960. Format: Purified. Applications: ELISA, IHC-P.
Key elements and design rationale
- Target: CD79b.
- Immunogen: A recombinant fragment of human CD79b protein was used as the immunogen for the CD79b antibody..
- Species reactivity: Human.
- Localization: Cell Surface.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
CD79 (also designated Ig Alpha/Ig beta) is a heterodimer composed of Alpha chains, designated CD79A or MB-1, and beta chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
